ReviewCancers2019
Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 2 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Response to targeted radionuclide therapy with [Frontiers in endocrinology · 2022Pooled it
- Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Guideline
- Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Pheochromocytoma Presenting as Spontaneous Adrenal Hemorrhage in a Normotensive Patient: A Case Report.Journal of clinical medicine · 2026Article
- Review
- The GAPP Aggressivity Score Correlates with Total Enriched Somatic Variant Burden in Sporadic Pheochromocytoma-A Pilot Study.Cancers · 2026Article
- Predominant catecholaminergic differentiation in tympanic paragangliomas: report of three consecutive cases.Virchows Archiv : an international journal of pathology · 2026Article
- A robust dual-readout ratiometric assay for dopamine based on NiMnRSC advances · 2026Article
- Bladder paraganglioma with lymph node metastasis treated by surgery with long-term recurrence-free survival: A case report.Urology case reports · 2026Article
- Case Report: When pancreatic cancer is not cancer: a rare case of pancreatic head paraganglioma with life-threatening delayed pseudoaneurysm bleeding.Frontiers in surgery · 2026Article
- Clinico-Radiological Presentation and Management of Gallbladder Paraganglioma: A Systematic Review.Cureus · 2026Review
- Current Understanding of Carotid Body Paraganglioma Management.Vascular specialist international · 2025Review
- Quantitative [EJNMMI reports · 2025Article
- Expanding the therapeutic horizon ofNagoya journal of medical science · 2025Review
- Long-Term Persistence of Glycemic Dysregulation in Patients With a History of Pheochromocytoma/Paraganglioma.The Journal of clinical endocrinology and metabolism · 2025Article
- Advances in multimodal imaging for adrenal gland disorders: integrating CT, MRI, and nuclear medicine.Japanese journal of radiology · 2025Review
- Case report and literature review of gallbladder paraganglioma in patient with inflammatory bowel disease.Journal of surgical case reports · 2025Article
- [A case report of malignant paraganglioma with lymph node and liver metastasis in the jugular foramen area].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025Article
- Massive pheochromocytoma causing adrenal crisis during surgery: a case report and review of the literature.Journal of medical case reports · 2025Review
- Clinical exome next‑generation sequencing panel for hereditary pheochromocytoma and paraganglioma diagnosis.Experimental and therapeutic medicine · 2025Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
Pheochromocytomas and paragangliomas (PCC/PGLs) are rare, mostly catecholamine-producing neuroendocrine tumors of the adrenal gland (PCCs) or the extra-adrenal paraganglia (PGL). They can be separated into three different molecular clusters depending on their underlying gene mutations in any of the at least 20 known susceptibility genes: The pseudohypoxia-associated cluster 1, the kinase signaling-associated cluster 2, and the Wnt signaling-associated cluster 3. In addition to tumor size, location (adrenal vs. extra-adrenal), multiplicity, age of first diagnosis, and presence of metastatic disease (including tumor burden), other decisive factors for best clinical management of PCC/PGL include the underlying germline mutation. The above factors can impact the choice of different biomarkers and imaging modalities for PCC/PGL diagnosis, as well as screening for other neoplasms, staging, follow-up, and therapy options. This review provides a guide for practicing clinicians summarizing current management of PCC/PGL according to tumor size, location, age of first diagnosis, presence of metastases, and especially underlying mutations in the era of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.